Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2006-10-25
2009-11-24
Nickol, Gary B (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S350000, C514S002600, C514S004300, C435S069100, C435S069500, C435S069700, C424S085100
Reexamination Certificate
active
07622556
ABSTRACT:
Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4791101 (1988-12-01), Adolf
patent: 5091176 (1992-02-01), Braatz et al.
patent: 5214131 (1993-05-01), Sano et al.
patent: 5258517 (1993-11-01), Zepp et al.
patent: 5264209 (1993-11-01), Mikayama et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5811388 (1998-09-01), Friend et al.
patent: 5811512 (1998-09-01), Hirschmann et al.
patent: 5888814 (1999-03-01), Kriegler et al.
patent: 5891418 (1999-04-01), Sharma
patent: 6180084 (2001-01-01), Ruoslahti et al.
patent: 6576239 (2003-06-01), Ruosiahiti et al.
patent: 6759509 (2004-07-01), King et al.
patent: 0 251 494 (1988-01-01), None
patent: 0 496 074 (1992-07-01), None
patent: 0 239 400 (1994-08-01), None
patent: WO 95/15979 (1995-06-01), None
patent: WO 98 10795 (1998-03-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 99 13329 (1999-03-01), None
patent: WO 99/13329 (1999-03-01), None
patent: WO 01/61017 (2001-08-01), None
Lohn et al., Leuk. Lymphoma, 2002, 43(2):407-413.
Yang et al., Mol. Immunol., 1995, vol. 32, pp. 873-881.
Helson, et al., Effect of Tumor Necrosis Factor on Cultured Human Melanoma Cells,Nature1975, 258, pp. 731-732.
Schraffordt et al., Hyperthermic Isolated Limb Perfusion with Tumour Necrosis Factor and Melphalan as Treatment of Locally Advanced or Recurrent Soft Tissue Sarcomas of the Extremities, Radiotherapy & Oncology 1998, 48: pp. 1-4.
Office Action dated Jul. 15, 2008, in related U.S. Appl. No. 11/338,842, 12 pgs.
Tabata et al., “Targeting of Tumor Necrosis Factor to Tumor by Use of Dextran and Metal Coordination,”Journal of Controlled Release 59, 1999, pp. 187-196.
Miyata et al., “Overcoming the Metastasis-Enhancing Potential of Human Tumor Necrosis Factor α by Introducing the Cell-Adhesive Arg-Gly-Asp Sequence,” J. Interferon and Cytokine Res., 1995, vo1. 15:161-169.
Arap W et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,” Science, American Association for the Advancement of Science, vol. 279, Jan. 16, 1998, pp. 377-380. XP000857470.
Carswell, et al., “An endotoxin-induced serum factor that causes necrosis of tumors,”Proc. Nat. Acad. Sci. USA, vol. 72(9):3666-3670 (1975), USA.
Celik, et al., “Demonstration of Immunogenicity with the Poorly Immunogenic B16 Melanoma,”Cancer Research, 43:3507-3510 (1983), USA.
Chen, et al., “Enhanced Anti-tumor Effect of an IFN-γ-EGF Fusion Protein,”Biomedical and Environmental Sciences, 10:387-395 (1997), CAPM.
Colombo, et al., “Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine
euroendocrine tumors,”J. Endocrinol. Invest., 16:841-843 (1993), Germany.
Corti, et al., “Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: effects of TNFα-soluble TNF receptor (p55) complex dissociation during assay incubations,”Journal of Immunological Methods, 177:191-198 (1994), Elsevier Science B.V., UK.
Corti, et al., “Tumor Targeting with Biotinylated Tumor Necrosis Factor α: Structure-Activity Relationships and Mechanism of Action on Avidin Pretargeted Tumor Cells,”Cancer Research, 58:3866-3872 (1998).
Corti, et al., “Upregulation of p75 Tumor Necrosis Factor Alpha Receptor inMycobacterium avium-Infected Mice: Evidence for a Functional Role,”Infection and Immunity, 67(11):5762-5767 (1999), American Society for Microbiology.
Curnis et al., “Targeted Delivery of Tumor Necrosis Factor Alpha (TNF) to Tumor Associated Vessels”, International Journal of Molecular Medicine, Spandidos, Athens, GA, vol. 6, No. Suppl. 1, Oct. 19, 2000, p. S72, XP001030678, ISSN: 1107-3756.
Curnis, et al., “Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13),”Nature Biotechnology, 15:1185-1190 (2000), USA.
Debs, et al., “Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats,”Cancer Research, 50:375-380 (1990), USA.
Debs, et al., “Liposome-Associated Tumor Necrosis Factor Retains Bioactivity in the Presence of Neutralizing Anti-Tumor Necrosis Factor Antibodies,”The Journal of Immunology, 143(4), 1192-1197 (1989), The American Association of Immunologists, USA.
Eggermont, et al., “Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas,”Annals of Surgery, 224(6):756-765 (1996), Lippincott-Raven Publishers.
Fiers, “Chapter 12 Biologic Therapy with TNF: Preclinical Studies,”Biologic Therapy of Cancer: Principles and Practice, 1995, pp. 295-327, JB Lippincott Company, Phila., PA.
Fraker, et al., “Chapter 13 Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion,”Biologic Therapy of Cancer: Principles and Practice, 1995, pp. 329-345, JB Lippincott Company, Phila., PA.
Gasparri, et al., “Tumor Pretargeting with Avidin Improves the Therapeutic Index of Biotinylated Tumor Necrosis Factor α in Mouse Models,”Cancer Research, 59:2917-2923 (1999).
Hattori et al.,J. Agric. Food Chem, 2000, vol. 49(9): pp. 3789-3794.
Hill, et al., Low-does tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion,British J. Surg., 80:995-997 (1993), Butterworth-Heinemann Ltd, UK.
Hoogenboom, et al., “Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins,”Molecular Immunology, 28(9):1027-1037 (1991), Pergamon Press, UK.
Koops, et al., “Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities,”Radiotherapy and Oncology, 48:1-4 (1998), Elsevier Science Ireland Ltd., UK.
Kost et al.,Gynecol. Oncol., 1999, vol. 72(3): pp. 392-401.
Li,énard, et al., “In Transit Metastases of Malignant Melanoma Treated by High Dose rTNFα in Combination with Interferon-γ and Melphalan in Isolation Perfusion,”World J. Surg., 16:234-240 (1992), Societe Internationale de Chirurgie, Belgium.
Ljunggren, et al., “Host Resistance Directed Selectively Against H-2-Deficient Lymphoma Variants,”J. Exp. Med., 162:1745-1759 (1985), The Rockefeller University Press, USA.
Loetscher, et al., “Human Tumor Necrosis Factor α (TNFα) Mutants with Exclusive Specificity for the 55-kDa or 75-kDa TNF Receptors,”The Journal of Biological Chemistry, 268(35):26350-26357 (1993), The American Society for Biochemistry and Molecular Biology, Inc., USA.
Luck et al.,Molecular Endrocrinology, 1991, vol. 5(12): pp. 1880-1886.
Mizuguchi, et al., “Tumor Necrosis Factor α-mediated Tumor Regression by the in vivo Transfer of Genes into the Artery That Leads to Tumors,”Cancer Research, 58:5725-5730 (1998).
Modorati, et al., Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results,British Journal of Ophthalmol., 78:19-23 (1994), UK.
Moro, et al., “Tumor Cell Targeting with Antibody-Avidin Complexes and Biotinylated Tumor Necrosis Factor α,”Cancer Research, 57:1922-1928 (1997), Italy.
Ostade, et al., “Human TNF mutants with selective activity on the p55 receptor,”Nature, 361:266-269 (1993), Belgium.
Paganelli, et al., “Clinical Application of the Avidin-Biotin System for Tumor Targeting,”Can. Therapy with Radiolabelled Antibodies, 239-254 (1995), CRC Press, Inc., UK.
Paganelli, et al., “Three-Step Monoclonal Antibody Tumor Targeting in Carcinoembryonic Antigen-Positive Patients,”Cancer Research, 51:5960-5966 (1991).
Palladino, et al., “Characterization of the Antitumor Act
Foley & Lardner LLP
Fondazione Centro San Raffaele Del Monte Tabor
Nickol Gary B
Xie Xiaozhen
LandOfFree
Modified cytokines for use in cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified cytokines for use in cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified cytokines for use in cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115879